Loading clinical trials...
Loading clinical trials...
An Open-Label, Phase II Study to Evaluate Safety, Tolerability, Antiviral Activity and Biochemical and Immunological Responses of L-FMAU (Clevudine) in Chronic Hepatitis B Patients of L-FMAU-201 Placebo Group
Conditions
Interventions
Clevudine
Locations
7
South Korea
Korea University Guro Hospital
Guro-dong, Guro-ku, Seoul, South Korea
Seoul National University
Yeongeon-dong, Jongno-Gu, Seoul, South Korea
Samsung Medical Center
Ilwon-dong, Kangnam-Gu, Seoul, South Korea
Yongdong Severance Hospital
Togok-tong, Kangnam-Gu, Seoul, South Korea
Asan Medical Center
P’ungnabi-dong, Songpa-Gu, Seoul, South Korea
Ewha Womans University Hospital
Mokdong, Yangchon-Gu, Seoul, South Korea
Start Date
June 1, 2003
Completion Date
February 1, 2005
Last Updated
October 17, 2012
NCT07024641
NCT06671093
NCT07275554
NCT03826433
NCT06885710
NCT06947499
Lead Sponsor
Bukwang Pharmaceutical
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions